These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8225386)

  • 1. Human complement factor B: functional properties of a recombinant zymogen of the alternative activation pathway convertase.
    Schwaeble W; Lüttig B; Sokolowski T; Estaller C; Weiss EH; Meyer zum Büschenfelde KH; Whaley K; Dippold W
    Immunobiology; 1993 Jul; 188(3):221-32. PubMed ID: 8225386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of chrysotile asbestos fibres with the complement system.
    Saint-Remy JM; Cole P
    Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in serum properdin factor B phenotype following human orthoptic liver transplantation.
    Hauptmann G; Tongio MM; Klein J; Mayer S; Cinqualbre J; Jeanblanc B; Kieny R
    Immunobiology; 1980; 158(1-2):76-81. PubMed ID: 7009411
    [No Abstract]   [Full Text] [Related]  

  • 7. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active sites in complement component C3 mapped by mutations at indels.
    Ogata RT; Ai R; Low PJ
    J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between the alternative complement pathway and proteases of the coagulation system.
    Kazatchkine MD; Jouvin MH
    Adv Exp Med Biol; 1984; 167():235-9. PubMed ID: 6561912
    [No Abstract]   [Full Text] [Related]  

  • 10. Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen.
    Sundsmo JS; Wood LM
    J Immunol; 1981 Sep; 127(3):877-80. PubMed ID: 6911148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
    Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
    J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a major serum DNA-binding protein as factor B of the alternative complement pathway.
    Gardner WD; Haselby JA; Hoch SO
    J Immunol; 1980 Jun; 124(6):2800-6. PubMed ID: 6989908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRIT peptide interacts with factor B and interferes with alternative pathway activation.
    Hui KM; Magnadóttir B; Schifferli JA; Inal JM
    Biochem Biophys Res Commun; 2006 May; 344(1):308-14. PubMed ID: 16600177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
    Kazatchkine MD; Fearon DT; Austen KF
    J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
    [No Abstract]   [Full Text] [Related]  

  • 18. Structure and activation of complement components C2 and factor B.
    Gagnon J
    Philos Trans R Soc Lond B Biol Sci; 1984 Sep; 306(1129):301-9. PubMed ID: 6149575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hemolytically inactive gene product of factor B.
    Mauff G; Federmann G; Hauptmann G
    Immunobiology; 1980; 158(1-2):96-100. PubMed ID: 6782013
    [No Abstract]   [Full Text] [Related]  

  • 20. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
    Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
    J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.